Clients will be able to move preclinical and clinical data from XB-BIS platform to IPA Software.

Ingenuity® Systems and TransMed Systems have linked their respective IPA® and XB Bio-Integration Suite (XB-BIS) platforms to facilitate research in the fields of personalized medicine and pharmacogenomics. The ability to move data between the packages means researchers can now take preclinical and clinical data managed and analyzed by XB-BIS directly into IPA, to analyze, model, and investigate omics data in support of studies into how genes affect response to drug treatment. The firms claim this ability will provide a clear workflow to analyze preclinical and clinical data in the context of signaling and metabolic pathways, networks, and cellular processes.

“Personalized medicine requires the ability to quickly translate large amounts of data into meaningful biological information,” notes Doug Bassett, Ph.D., CSO, and CTO at Ingenuity. He says the partnership with TransMed will provide “a streamlined platform from which researchers and clinicians will be able to collect and analyze data, link genotypes to phenotypes, identify potential biomarkers, generate powerful and informed hypotheses, and understand the molecular differences between patient populations for improved diagnostics and therapeutics.”

Ingenuity is dedicated to the development of technologies that enable researchers to effectively search, explore, visualize, and analyze biological and chemical findings related to genes, proteins, and small molecules. Its IPA software is powered by the Ingenuity Knowledge Base, which the firm claims is the largest knowledge base of its kind, including modeled relationships between proteins, genes, complexes, cells, tissues, drugs, pathways, and diseases. The Knowledge Base encompasses information from a broad range of published biomedical literature, internally curated knowledge, and a wide variety of validated external sources and databases,

TransMed works alongside clinicians and researchers to develop software tools that facilitate the analysis and application of patient and sample data, including EMR (electronic medical record) data. The firm’s flagship XB-BIS platform is a fully integrated biological and medical informatics solution for translational research. TransMed says that within XB-BIS longitudinal, phenotypic, environmental, and protocol data is directly integrated with molecular data generated from experiments performed on samples derived from a subject. Researchers are able to access multivariant data sources, including both internal data and external public data stores, as well as create unique patient cohorts, analyze data utilizing a broad spectrum of analytic and statistical tools, and create unique, testable hypotheses.

Previous articleCylene Looks to Horizon to Identify Genetic Basis of Response to Oral Anticancer Drug
Next articleNew Voltage-Sensitive Cell Type Directs Stem-Cell Daughters to Trigger Cancer